Flu vaccines 48% effective so far this season, CDC says

So far this season, flu vaccines have been 48% effective in preventing medical visits, according to a CDC estimate.

This year’s flu vaccine is working for almost half of recipients, the CDC says in an update on what it’s calling a “moderate” season. But, as of data ending Feb. 4, government experts don’t expect the season to come to a close right away.

CDC anticipates “several more weeks” of flu activity in parts of the U.S., according to an agency update. So far, vaccines have been 48% effective in preventing flu-related medical visits, the CDC estimates.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

That compares to 59% for last year and 19% for the year before, according to the CDC. Over 10 previous flu seasons, vaccine effectiveness has fluctuated each year, often ending up with a percentage in the 40s or 50s.

Separately this year, CDC experts recommended against any use of AstraZeneca’s FluMist on efficacy concerns from three previous seasons. AZ said it’s working to assess the situation.

All year round, experts monitor the virus and select strains for the upcoming season. But, in an effort to improve on so-so efficacy and avoid strain drift, several biopharma companies are working on “universal” vaccines that fight a range of strains over multiple years.

Sanofi, the world’s largest flu vaccine manufacturer, in late 2015 unveiled its work in the area. It announced a vax project dubbed Cobra that’s designed to protect against multiple strains by using common sequences the strains share.

Other companies and groups that have gotten into universal flu vaccine work include Johnson & Johnson’s Crucell and Scripps Research Institute, plus biotechs BiondVax and FluGen.

Suggested Articles

Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo—and it’s bringing in Bayer to help.

When AstraZeneca sold its Avlon, England plant in 2016, it thought its liabilities were over. Former employees said the drugmaker broke its promises.

Pharmacy chain Rite Aid has partnered with Google to have their drug recycling stations easily searchable on Google Maps.